SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 135 filers reported holding SYNDAX PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 0.21 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $143 | -92.5% | 9,841 | -89.1% | 0.00% | -90.9% |
| Q1 2023 | $1,904 | +981.8% | 90,137 | +1206.5% | 0.02% | +1000.0% |
| Q4 2022 | $176 | -100.0% | 6,899 | -69.8% | 0.00% | -71.4% |
| Q3 2022 | $549,000 | -2.7% | 22,866 | -22.0% | 0.01% | +16.7% |
| Q2 2022 | $564,000 | +32.4% | 29,307 | +19.6% | 0.01% | +100.0% |
| Q1 2022 | $426,000 | +252.1% | 24,499 | +343.5% | 0.00% | +200.0% |
| Q4 2021 | $121,000 | -77.6% | 5,524 | -80.4% | 0.00% | -66.7% |
| Q3 2021 | $540,000 | +208.6% | 28,250 | +260.7% | 0.00% | +200.0% |
| Q1 2021 | $175,000 | +63.6% | 7,832 | +62.9% | 0.00% | 0.0% |
| Q4 2020 | $107,000 | -51.4% | 4,809 | -67.5% | 0.00% | -50.0% |
| Q2 2020 | $220,000 | +300.0% | 14,812 | +40.3% | 0.00% | +100.0% |
| Q1 2019 | $55,000 | – | 10,558 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,025,000 | $21,648,000 | 10.42% |
| Foresite Capital Management IV, LLC | 875,000 | $18,480,000 | 9.59% |
| Kynam Capital Management, LP | 3,205,986 | $67,710,424 | 8.74% |
| Frazier Life Sciences Management, L.P. | 3,708,838 | $78,330,659 | 5.67% |
| ACUTA CAPITAL PARTNERS, LLC | 330,000 | $6,969,600 | 5.13% |
| Paradigm Biocapital Advisors LP | 2,274,512 | $48,037,693 | 4.55% |
| Eversept Partners, LP | 2,209,057 | $46,655,284 | 3.25% |
| DAFNA Capital Management LLC | 447,073 | $9,442,182 | 2.83% |
| COMMODORE CAPITAL LP | 853,884 | $18,034,030 | 2.75% |
| Avidity Partners Management LP | 3,865,300 | $81,635,136 | 2.71% |